since Cryer Pharmaceuticals and The Core have begun a new chapter in common endevours, I would like to use the opportunity and introduce myself in person - Martin McKinsey, CEO of AP Manufacturing.
Your company requested that captured pilots positively identified as Outcast be brought for research purposes to Atka Station in Sigma 17. Thus I am sure you will be pleased to learn, that the crew of the Quirinus had collected and delivered 10 specimen to your disposal after having successfully intercepted an arms shipment heading for Omicron Beta. Your welcome Mr. Calderon.
At this point I wish to express my personal interrest in your study of Outcast physiology and their longterm, trans-generational cardamine intake. My close friend, Dr. Engele, whose own field of study comprises bodily enhancement tech, would be most delighted to learn about some of the less apparent insights your scientists collected - exclusively for the sake of science per se, if you know what I mean.
As the head of APM I entertain the prospect of further expanding our cooperation and am sincerely looking forward to your response.
It is a pleasure to meet you. It is pleasing to see that the agreement between our two organizations is seeing fruition. Especially when you have delivered them in tact and alive. It makes such studies more... how shall I say, effective. I am already receiving reports from our Scientists on Atka concerning these Outcasts, and the verbiage certainly indicates a level of excitement that I have not seen in some time. I must personally thank you for such a delivery.
Now, as to your interest. Before I share any details of our work, I would like to invite you and Dr. Engele to Atka, at your convenience. That way we can ensure you both are fully NDA'd, that no transmissions are sent in or out while viewing our labs, as well as able to speak with our scientists directly and view our work in person. Security is of our utmost concern, whether from an intern or all the way up to a C-Level executive.
Please let me know when you and your counterpart are able to visit Atka, and I will ensure my schedule is cleared to meet you both.
I am glad that the aquired specimen have proven useful to your study. We will make sure to keep Atka supplied on further test subjects as frequent as possible.
While I am still on my way back from Liberty to Core space, I talked to Dr. Engele already about your invitation. We will be happy to visit your facilities as soon as my flagship vacates Kusari space, which will be in 2 days sharp. You may expect our arrival then. I may add, that your security concerns are naturally understandable - to learn that the body of knowledge Cryer has developed over the years (perhaps some of it being of most delicate matter) is safely contained evokes confidence in your modus operandi - who but the APM appreciates proper safekeeping of data? We would not want certain findings to fall into the wrong hands.
I am sure that our meeting will produce pleasing results for both our parties, thus I am looking forward to it.
I appreciate the note of understanding regarding our security protocols. Sadly in this day in age, even the most trusted of organizations can have infestations from unsavory individuals, that create risk of a security breach. Cryer included internally, hence only those with a full background check and authorized clearance are allowed in our labs on Atka.
Upon your arrival on Atka, our head of security will meet you both, provide the necessary documents for signing, as well as request that any personal comm devices be submitted for safe keeping during your stay. They will then escort you to one of our labs that we have secured for your arrival that will hopefully provide a glimpse at some of the work we do within Atka.
I should make mention that I will be away on a business trip beginning later today, that I expect will last a few days. It is entirely up to you if you would rather wait for my return to visit Atka, otherwise our CAO Oscar Sanders will be available to meet you as well in my stead.
Dr. Engele and I will be happy to take the proverbial glimpse on the work Cryer scientists have accomplished on Atka, however I personally would like to kindly insist on your accompanying us - for reasons that, I am sure, a man of vision like yourself can fully understand.
This channel is encrypted with invincible Core protocols, thus I propose we be frank with each other.
Both Cryer Pharmaceuticals and AP Manufacturing maintain divisions dedicated to areas of reseach frown upon by most lawful entities in all of Sirius. Advocates of humanity may fit the cover of public politics but are less than redundant in pursuit of greater ideas. It is because of men like you and me that human kind, fragile as it is, has even had the slightest of chances of surviving throughout millenia of disease, decay and madness; men devoted to mastering the elements, engaged in developing sciences, striving for knowledge by any means neccessary, despite ignorance and simple mindedness of their supposed kin. We both know that what can be achieved at this moment of time is limited by the resources and latitude we can afford to spare. I believe this is the point at which men like you and me must realise that they need to form partnerships - for science sake.
Here is how I propose we proceed:
1. The most gifted minds in the area of phisiological anomalies and conditioned proto-evolutionary research from both our parties form a joint reseach cell. If you wish, this division may be deployed on Atka in your capable, caring hands.
2. All research conducted by this division shall be focused on isolating stimulated genetic development of phisiological features with the aim of outlining reproducable, synthesizable means of application.
3. In the spirit of equal contribution all methodology, results and produce within this division are accessible by you and me, as well as limited personel of our trust at all time.
4. Further application of achieved results within our respective companies is of equal disconcern, unless otherwise agreed upon.
5. Both sides oblige to handle this joint project with utmost confidentiality. In the event of outside inquiry any knowledge of this will be denied.
Do you Mr. Calderon concur with my proposal? I sincerely believe that a joint enterprise will not only benefit the progress of the respective research conducted by our companies, but also, as stated before, science per se. Thus, with all due respect to Mr. Sanders, I will be happy to reschedule our visit to meet your undivided attention.
Now that I have returned from my prior obligations, I can address your encrypted message more thoroughly.
Having reviewed your proposal numerous times, we are in complete agreement that the state of Sirius does not belong to the simple-minded denizens, who are morally obliged to create numerous barriers that often times prevent the study and advances in both the technological and biological fields. It then falls to the few enlightened individuals, who are not restricted by the petty concept of morality, to provide Sirius with advances that allow a longer, better, more fulfilled life, no matter the cost. As such, it is my belief that such a joint effort would provide many positives, both financially as well as utilizing the resources available to each of our respective organizations.
With that said, I accept your proposal as it stands, though will expect and require that an official contract be drafted that will require both of our signatures to ensure all avenues are covered with such a joint effort, such ownership of proprietary technology and an equal share in profits based on the results of said efforts.
During this time, all matters related to the aforementioned will be kept private on my personal network, until such a time that we have agreed on the finer details. At that point, I will provide the necessary details to the appropriate board members at Cryer, which should then mark the start of constructing space aboard Atka for such an endeavor.
What I would ask of you Mr. McKinsey, is to draft up the terms of agreement, which we can review and amend as needed, until both parties are satisfied with the terms outlined.
This marks the beginning of a long and fruitful relationship Mr. McKinsey between the Core and Cryer. I look forward to seeing the fruits of our labor, as well as the profits that will bring.
I am pleased to hear that you and your associates concur with our exitus acta probat understanding of the greater good that resides in pursuit of ever greater knowledge.
As requested, I have taken the time to draft a collaboration agreement that will lay foundations of our relationship and equally benefit our respective parties. You will find the document attached below.
On part of APM, Dr. J. Engele and his research team will be assigned to this project (which in my whimsy I have christened FONS IUVENTAE). The Doctor will also take seat in the expert committee along with scientists of his choosing. As I am told he is very eager to make acquaintence with the brilliant minds that shall be assigned on part of Cryer. For the management office I shall delegate one of my trusted advisors later on as I have not yet decided on whom to grant this privilege.
In the meantime I am looking forward to your response and naturally, to a bright future of cooperation between our companies.
AP Manufacturing, a corporation organized under the laws of Imperium Omicronis, having its principal place of business at Alabama Shipyard, Omicron Rho
(hereinafter referred to as "APM")
and
Cryer Pharmaceuticals, a corporation organized under the laws of The Republic of Liberty, having its place of business at Planet Denver, Colorado
(hereinafter referred to as "CRYER").
In consideration of the mutual covenants and obligations set forth herein, the Parties hereto, intending to be legally bound, agree on establishing a joint lab for pharmacological and genetic research hereinafter referred to as "FONS IUVENTAE" with regard to the following conditions:
1. Purpose
1.1. The FONS IUVENTAE will be the hub of the cooperative relationship between both Parties and an effective way of conducting research in the form of a joint endeavor. The purpose of establishment is to:
1.1.1. Examine the physiological characteristics of live human subjects positively identified as having developed or acquired Cardamine dependency, inherited genetic mutations characteristic of trans-generative Cardamine intake or otherwise indicating abnormal physiological features.
1.1.2. Study the effects of both long term and short term exposure of test subjects referred to in 1.1.1. to various substances and isolate stimulated genetic development of certain physiological features with the aim of outlining reproducible, synthesizable means of application.
1.2. Standing purposes may be redefined at any time by means of extension to this agreement, with the consent of both Parties.
2. Location and execution
2.1. The primary place of operation for FONS IUVENTAE will be established on Atka Research Station in Sigma 17. If circumstances prove it necessary, relocation to a secondary site at Alabama Shipyard in Omicron Rho may be considered with the consent of APM.
2.2. FONS IUVENTAE will be provided with an Expert Committee and Management Office at its current place of operation as follows:
2.2.1. The Expert Committee will be composed of the related personnel of both Parties and have one chairman and several members. Chairman will be held by the member assigned by each Party in turn. The responsibility of the Expert Committee is: determine the work projects and contents of the FONS IUVENTAE; evaluate its project research, development, consultancy and achievement translation.
2.2.2. The Management Office will be an administrative office of the FONS IUVENTAE. Each Party will assign one member to it. The responsibility of this Office is: take charge of the daily work of FONS IUVENTAE; convene meetings of the Expert Committee.
3. Application and intellectual property
3.1. All scientific results achieved by FONS IUVENTAE are shared intellectual property of CRYER and APM in equal amount.
3.2. Both Parties may apply any scientific results of this collaboration to other branches of their respective operations without knowledge or consent of one another provided that the derivatives of such applications serve internal purposes only and are not by any means marketed or distributed to third parties.
3.3. Derivatives produced by either Party applied for commercial purposes, such as product marketing or license distribution are subject to a 50% stake of interest per sale unit or total licensing profit to benefit the other Party.
3.4. Neither Party is under any circumstances allowed to sell or otherwise discard its share of the intellectual property thus acquired to third parties without the knowledge and consent of the other Party. Transfer of the respective share of that property between CRYER and APM is possible under mutual agreement.
4. Non-disclosure
4.1. Both Parties agree irrevocably to non-disclosure of the research conducted within the frame of this agreement, including but not limited to identity of the test subjects, identity of the assigned staff, tested substances, achieved results, general modus operandi, towards third parties, including those involved in other legal agreements with either Party.
4.2. Further applications of any results achieved by FONS IUVENTAE do not influence the hereby established non-disclosure obligation.
5. Profit Distribution
5.1. Profits will be distributed to both Parties on a pro-rata basis with consideration of share and interest referred to in 3.3. depending on the technology source of translated results (i.e. new products), product marketing as well as market performance of products.
5.2. Optional market project cooperation, along with specific distribution percentages are to be agreed upon by both Parties according to the specific situations of different projects should a such joint market project be agreed on in the course of collaboration.
6. Place of jurisdiction
The general place of jurisdiction for this agreement is Planet Nauru under the laws of Imperium Omicronis without regard to the conflict of law principles thereof that may dictate application of the laws of The Republic of Liberty or any other state.
7. Term and termination
7.1. Unless earlier terminated pursuant to 7. the term of this Agreement shall commence on the effective date and shall remain in full force and effect for an indefinite period.
7.2. Either Party shall have the right, at any time after the effective date, to terminate this Agreement in its entirety by providing not less than 12 weeks prior written notice of such termination.
8. Force majeure
No Party (or any of its Affiliates) shall be held liable or responsible to the other Party (or any of its Affiliates), or be deemed to have defaulted under or breached the Agreement, for failure or delay by such Party in fulfilling or performing any term of the Agreement when such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party (or any of its Affiliates), including embargoes, war, acts of war (whether war be declared or not), insurrections, civil commotions, or omissions or delays in acting by any governmental authority.
9. Disclaimer
CRYER and APM each acknowledge that the relationship between the two Parties established by this Agreement shall not constitute a partnership or any type of fiduciary relationship. Neither CRYER nor APM shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior consent of the other Party to do so.
![[+]](/forums/images/collapse_collapsed.png "[+]")
Attachments:![[Image: OvZl9fJl.png]](http://i.imgur.com/OvZl9fJl.png)
![[Image: 8Vg6Lkel.png]](http://i.imgur.com/8Vg6Lkel.png)
![[Image: sPJPwjul.png]](http://i.imgur.com/sPJPwjul.png)
![[Image: 19584ee322.gif]](https://puu.sh/w3Or6/19584ee322.gif)